483 related articles for article (PubMed ID: 33093455)
1. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
[TBL] [Abstract][Full Text] [Related]
2. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
3. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
[TBL] [Abstract][Full Text] [Related]
6. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
7. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
8. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
Yaw ACK; Chan EWL; Yap JKY; Mai CW
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
[TBL] [Abstract][Full Text] [Related]
9. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
Zhang W; Ba G; Tang R; Li M; Lin H
Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
[TBL] [Abstract][Full Text] [Related]
10. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
[TBL] [Abstract][Full Text] [Related]
11. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
13. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
14. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
16. NLRP3 inflammasome activates interleukin-23/interleukin-17 axis during ischaemia-reperfusion injury in cerebral ischaemia in mice.
Wang H; Zhong D; Chen H; Jin J; Liu Q; Li G
Life Sci; 2019 Jun; 227():101-113. PubMed ID: 31002919
[TBL] [Abstract][Full Text] [Related]
17. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke.
Ismael S; Zhao L; Nasoohi S; Ishrat T
Sci Rep; 2018 Apr; 8(1):5971. PubMed ID: 29654318
[TBL] [Abstract][Full Text] [Related]
19. Down-expression of the NLRP3 inflammasome delays the progression of diabetic retinopathy.
Ge K; Wang Y; Li P; Li M; Zhang W; Dan H; Hu X; Zhou J; Yang Q; Wang J; Song Z
Microvasc Res; 2022 Jan; 139():104265. PubMed ID: 34662588
[TBL] [Abstract][Full Text] [Related]
20. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]